Cargando…
Immunohistochemical staining with non-phospho β-catenin as a diagnostic and prognostic tool of COX-2 inhibitor therapy for patients with extra-peritoneal desmoid-type fibromatosis
BACKGROUND: Immunohistochemical staining with conventional anti-β-catenin antibody has been applied as a diagnostic tool for desmoid-type fibromatosis (DF). This study aimed to evaluate the diagnostic and prognostic value of immunohistochemical staining with anti-non-phospho β-catenin antibody, whic...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5576243/ https://www.ncbi.nlm.nih.gov/pubmed/28851389 http://dx.doi.org/10.1186/s13000-017-0654-z |
_version_ | 1783260162784493568 |
---|---|
author | Sakai, Tomohisa Nishida, Yoshihiro Hamada, Shunsuke Koike, Hiroshi Ikuta, Kunihiro Ota, Takehiro Ishiguro, Naoki |
author_facet | Sakai, Tomohisa Nishida, Yoshihiro Hamada, Shunsuke Koike, Hiroshi Ikuta, Kunihiro Ota, Takehiro Ishiguro, Naoki |
author_sort | Sakai, Tomohisa |
collection | PubMed |
description | BACKGROUND: Immunohistochemical staining with conventional anti-β-catenin antibody has been applied as a diagnostic tool for desmoid-type fibromatosis (DF). This study aimed to evaluate the diagnostic and prognostic value of immunohistochemical staining with anti-non-phospho β-catenin antibody, which might more accurately reflect the aggressiveness of DF, in comparison to the conventional anti-β-catenin antibody. METHODS: Between 2003 and 2015, 40 patients with extra-peritoneal sporadic DF were prospectively treated with meloxicam or celecoxib, a COX-2 inhibitor, therapy. The efficacy of this treatment was evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST). Immunohistochemical staining was performed on formalin-fixed material to evaluate the expression of β-catenin and non-phospho β-catenin, and the positivity was grouped as negative, weak, moderate, and strong. DNA was isolated from frozen tissue or formalin-fixed materials, and the CTNNB1 mutation status was determined by direct sequencing. RESULTS: Of the 40 patients receiving COX-2 inhibitor treatment, there was one with complete remission, 12 with partial remission, 7 with stable disease, and 20 with progressive disease. The mutation sites in CTNNB1 were detected in 22 (55%) of the 40 cases: T41A (17 cases), S45F (3 cases), and T41I and S45P (1 each). The positive nuclear expression of non-phospho β-catenin showed a significant correlation with positive CTNNB1 mutation status detected by Sanger method (p = 0.025), and poor outcome in COX-2 inhibitor therapy (p = 0.022). In contrast, nuclear expression of β-catenin did not show a significant correlation with either CTNNB1 mutation status (p = 0.43) or outcome of COX-2 inhibitor therapy (p = 0.38). CONCLUSIONS: Nuclear expression of non-phospho β-catenin might more appropriately reflect the biological behavior of DF, and immunohistochemical staining with non-phospho β-catenin could serve as a more useful diagnostic and prognostic tool of COX-2 inhibitor therapy for patients with DF. |
format | Online Article Text |
id | pubmed-5576243 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-55762432017-08-30 Immunohistochemical staining with non-phospho β-catenin as a diagnostic and prognostic tool of COX-2 inhibitor therapy for patients with extra-peritoneal desmoid-type fibromatosis Sakai, Tomohisa Nishida, Yoshihiro Hamada, Shunsuke Koike, Hiroshi Ikuta, Kunihiro Ota, Takehiro Ishiguro, Naoki Diagn Pathol Research BACKGROUND: Immunohistochemical staining with conventional anti-β-catenin antibody has been applied as a diagnostic tool for desmoid-type fibromatosis (DF). This study aimed to evaluate the diagnostic and prognostic value of immunohistochemical staining with anti-non-phospho β-catenin antibody, which might more accurately reflect the aggressiveness of DF, in comparison to the conventional anti-β-catenin antibody. METHODS: Between 2003 and 2015, 40 patients with extra-peritoneal sporadic DF were prospectively treated with meloxicam or celecoxib, a COX-2 inhibitor, therapy. The efficacy of this treatment was evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST). Immunohistochemical staining was performed on formalin-fixed material to evaluate the expression of β-catenin and non-phospho β-catenin, and the positivity was grouped as negative, weak, moderate, and strong. DNA was isolated from frozen tissue or formalin-fixed materials, and the CTNNB1 mutation status was determined by direct sequencing. RESULTS: Of the 40 patients receiving COX-2 inhibitor treatment, there was one with complete remission, 12 with partial remission, 7 with stable disease, and 20 with progressive disease. The mutation sites in CTNNB1 were detected in 22 (55%) of the 40 cases: T41A (17 cases), S45F (3 cases), and T41I and S45P (1 each). The positive nuclear expression of non-phospho β-catenin showed a significant correlation with positive CTNNB1 mutation status detected by Sanger method (p = 0.025), and poor outcome in COX-2 inhibitor therapy (p = 0.022). In contrast, nuclear expression of β-catenin did not show a significant correlation with either CTNNB1 mutation status (p = 0.43) or outcome of COX-2 inhibitor therapy (p = 0.38). CONCLUSIONS: Nuclear expression of non-phospho β-catenin might more appropriately reflect the biological behavior of DF, and immunohistochemical staining with non-phospho β-catenin could serve as a more useful diagnostic and prognostic tool of COX-2 inhibitor therapy for patients with DF. BioMed Central 2017-08-29 /pmc/articles/PMC5576243/ /pubmed/28851389 http://dx.doi.org/10.1186/s13000-017-0654-z Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Sakai, Tomohisa Nishida, Yoshihiro Hamada, Shunsuke Koike, Hiroshi Ikuta, Kunihiro Ota, Takehiro Ishiguro, Naoki Immunohistochemical staining with non-phospho β-catenin as a diagnostic and prognostic tool of COX-2 inhibitor therapy for patients with extra-peritoneal desmoid-type fibromatosis |
title | Immunohistochemical staining with non-phospho β-catenin as a diagnostic and prognostic tool of COX-2 inhibitor therapy for patients with extra-peritoneal desmoid-type fibromatosis |
title_full | Immunohistochemical staining with non-phospho β-catenin as a diagnostic and prognostic tool of COX-2 inhibitor therapy for patients with extra-peritoneal desmoid-type fibromatosis |
title_fullStr | Immunohistochemical staining with non-phospho β-catenin as a diagnostic and prognostic tool of COX-2 inhibitor therapy for patients with extra-peritoneal desmoid-type fibromatosis |
title_full_unstemmed | Immunohistochemical staining with non-phospho β-catenin as a diagnostic and prognostic tool of COX-2 inhibitor therapy for patients with extra-peritoneal desmoid-type fibromatosis |
title_short | Immunohistochemical staining with non-phospho β-catenin as a diagnostic and prognostic tool of COX-2 inhibitor therapy for patients with extra-peritoneal desmoid-type fibromatosis |
title_sort | immunohistochemical staining with non-phospho β-catenin as a diagnostic and prognostic tool of cox-2 inhibitor therapy for patients with extra-peritoneal desmoid-type fibromatosis |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5576243/ https://www.ncbi.nlm.nih.gov/pubmed/28851389 http://dx.doi.org/10.1186/s13000-017-0654-z |
work_keys_str_mv | AT sakaitomohisa immunohistochemicalstainingwithnonphosphobcateninasadiagnosticandprognostictoolofcox2inhibitortherapyforpatientswithextraperitonealdesmoidtypefibromatosis AT nishidayoshihiro immunohistochemicalstainingwithnonphosphobcateninasadiagnosticandprognostictoolofcox2inhibitortherapyforpatientswithextraperitonealdesmoidtypefibromatosis AT hamadashunsuke immunohistochemicalstainingwithnonphosphobcateninasadiagnosticandprognostictoolofcox2inhibitortherapyforpatientswithextraperitonealdesmoidtypefibromatosis AT koikehiroshi immunohistochemicalstainingwithnonphosphobcateninasadiagnosticandprognostictoolofcox2inhibitortherapyforpatientswithextraperitonealdesmoidtypefibromatosis AT ikutakunihiro immunohistochemicalstainingwithnonphosphobcateninasadiagnosticandprognostictoolofcox2inhibitortherapyforpatientswithextraperitonealdesmoidtypefibromatosis AT otatakehiro immunohistochemicalstainingwithnonphosphobcateninasadiagnosticandprognostictoolofcox2inhibitortherapyforpatientswithextraperitonealdesmoidtypefibromatosis AT ishiguronaoki immunohistochemicalstainingwithnonphosphobcateninasadiagnosticandprognostictoolofcox2inhibitortherapyforpatientswithextraperitonealdesmoidtypefibromatosis |